

Amendment to the Claims:

Please amend the claims as follows:

Please cancel claim 26, without prejudice or disclaimer.

This listing of claims will replace all prior versions, and listing, of claims in the application:

Listing of Claims:

Claims 1-45 (Cancelled)

46. (Currently amended) A method of blocking or inhibiting Apo-3 receptor, comprising exposing mammalian cells expressing Apo-3 receptor to an effective amount of anti-Apo-3 antibody, wherein said antibody (a) comprises an antigen binding site which binds to an Apo-3 receptor polypeptide comprising ~~amino acid residues 1 to 417 of SEQ ID NO:6 or a immunogenic fragment thereof or an extracellular domain sequence of Apo-3 receptor polypeptide which comprises amino acid residues 25 to 198 of SEQ ID NO:6~~ and (b) blocks or inhibits Apo-3 receptor induced apoptosis in said mammalian cells or Apo-3 receptor activation of NF-kB in said mammalian cells.

47. (Previously presented) The method of claim 46 wherein said anti-Apo-3 antibody is a chimeric antibody.

48. (Previously presented) The method of claim 46 wherein said anti-Apo-3 antibody is a humanized antibody.

49. (Previously presented) The method of claim 46 wherein said anti-Apo-3 antibody is a human antibody.

50. (Previously presented) The method of claim 46 wherein said anti-Apo-3 antibody is a monovalent antibody.

51. (Previously presented) The method of claim 50 wherein said monovalent antibody is a Fab fragment.

52. (Previously presented) The method of claim 46 wherein said anti-Apo-3 antibody is labeled with a detectable moiety capable of directly or indirectly producing a signal.

53. (Previously presented) The method of claim 52 wherein said detectable moiety is a radioisotope, fluorescent compound or chemiluminescent compound.

54. (Previously presented) The method of claim 46 wherein said mammalian cells are exposed to said anti-Apo-3 antibody *in vivo*.

55. (Previously presented) The method of claim 46 wherein said anti-Apo-3 antibody blocks or inhibits Apo-3 receptor induced apoptosis in said mammalian cells.

56. (Currently amended) A method of blocking or inhibiting Apo-3 receptor, comprising exposing mammalian cells expressing Apo-3 receptor to an effective amount of Apo-3 receptor immunoadhesin, wherein said immunoadhesin (a) comprises an Apo-3 receptor polypeptide comprising ~~amino acid residues 1 to 417 of SEQ ID NO:6~~ or an immunogenic fragment thereof and (b) blocks or inhibits Apo-3 receptor induced apoptosis in said mammalian cells or Apo-3 receptor activation of NF-kB in said mammalian cells.

57. (Previously presented) The method of claim 56 wherein said Apo-3 receptor immunoadhesin comprises an immunoglobulin constant region.

58. (Previously presented) The method of claim 56 wherein said fragment of the Apo-3 receptor polypeptide comprises amino acid residues 1 to 198 of SEQ ID NO:6.

59. (Previously presented) The method of claim 56 wherein said Apo-3 receptor immunoadhesin blocks or inhibits Apo-3 receptor induced apoptosis in said mammalian cells.

60. (Previously presented) The method of claim 56 wherein said mammalian cells are exposed to said Apo-3 receptor immunoadhesin *in vivo*.

61. (New) The method of claim 56, wherein the Apo-3 receptor comprises amino acid residues 1 to 417 of SEQ ID NO:6 or amino acid residues 25 to 198 of SEQ ID NO:6.

62. (New) The method of claim 56, wherein the Apo-3 receptor comprises amino acid residues 338 to 417 of SEQ ID NO:6.

63. (New) The method of claim 56, wherein the Apo-3 receptor comprises a soluble, truncated or secreted form of the Apo-3 receptor.

64. (New) The method of claim 46, wherein the Apo-3 receptor comprises amino acid residues 1 to 417 of SEQ ID NO:6 or amino acid residues 25 to 198 of SEQ ID NO:6.

65. (New) The method of claim 46, wherein the Apo-3 receptor comprises amino acid residues 338 to 417 of SEQ ID NO:6.

66. (New) The method of claim 46, wherein the Apo-3 receptor comprises a soluble, truncated or secreted form of the Apo-3 receptor.